Literature DB >> 30247774

Selective serotonin reuptake inhibitor and selective serotonin and norepinephrine reuptake inhibitor use and risk of fractures in adults: A systematic review and meta-analysis.

Vladimir Khanassov1, Jingyi Hu2, David Reeves2, Harm van Marwijk2.   

Abstract

OBJECTIVE: To evaluate the association between selective serotonin reuptake inhibitor (SSRI) and selective serotonin and norepinephrine reuptake inhibitor (SNRI) use and risk of fractures in older adults.
METHODS: We systematically identified and analyzed observational studies comparing SSRI/SNRI use for depression with non-SSRI/SNRI use with a primary outcome of risk of fractures in older adults. We searched for studies in MEDLINE, PsycINFO, Embase, DARE (Database of Abstracts or Reviews of Effects), the Cochrane Library, and Web of Science clinical trial research registers from 2011 for SSRIs and 1990 for SNRIs to November 29, 2016.
RESULTS: Thirty-three studies met our inclusion criteria; 23 studies were included in meta-analysis: 9 case-control studies and 14 cohort studies. A 1.67-fold increase in the risk of fracture for SSRI users compared with nonusers was observed (relative risk 1.67, 95% CI 1.56-1.79, P = .000). The risk of fracture increases with their long-term use: within 1 year, the risk is 2.9% or 1 additional fracture in every 85 users; within 5 years, the risk is 13.4% or 1 additional fracture in every 19 users. In meta-regression, we found that the increase in risk did not differ across age groups (odds ratio = 1.006; P = .173). A limited number of studies on SNRI use and the risk of fractures prevented us from conducting a meta-analysis.
CONCLUSIONS: Our systematic review showed an association between risk of fracture and the use of SSRIs, especially with increasing use. Age does not increase this risk. No such conclusions can be drawn about the effect of SNRIs on the risk of fracture because of a lack of studies.
© 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  risk of fractures; selective serotonin and norepinephrine reuptake inhibitors; selective serotonin reuptake inhibitors

Mesh:

Substances:

Year:  2018        PMID: 30247774     DOI: 10.1002/gps.4974

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  5 in total

1.  Association of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review.

Authors:  Elena Dragioti; Marco Solmi; Angela Favaro; Paolo Fusar-Poli; Paola Dazzan; Trevor Thompson; Brendon Stubbs; Joseph Firth; Michele Fornaro; Dimitrios Tsartsalis; Andre F Carvalho; Eduard Vieta; Philip McGuire; Allan H Young; Jae Il Shin; Christoph U Correll; Evangelos Evangelou
Journal:  JAMA Psychiatry       Date:  2019-12-01       Impact factor: 21.596

2.  Opioid and Benzodiazepine Substitutes: Impact on Drug Overdose Mortality in Medicare Population.

Authors:  Yong-Fang Kuo; Victor Liaw; Xiaoying Yu; Mukaila A Raji
Journal:  Am J Med       Date:  2022-03-25       Impact factor: 5.928

Review 3.  Antidepressants and Vertebral and Hip Risk Fracture: An Updated Systematic Review and Meta-Analysis.

Authors:  Renato de Filippis; Michele Mercurio; Giovanna Spina; Pasquale De Fazio; Cristina Segura-Garcia; Filippo Familiari; Giorgio Gasparini; Olimpio Galasso
Journal:  Healthcare (Basel)       Date:  2022-04-26

Review 4.  Molecular actions of sex hormones in the brain and their potential treatment use in anxiety disorders.

Authors:  Miriam Pillerová; Veronika Borbélyová; Michal Pastorek; Vladimír Riljak; Július Hodosy; Karyn M Frick; L'ubomíra Tóthová
Journal:  Front Psychiatry       Date:  2022-09-08       Impact factor: 5.435

5.  Multinational Investigation of Fracture Risk with Antidepressant Use by Class, Drug, and Indication.

Authors:  Robyn Tamblyn; David W Bates; David L Buckeridge; William G Dixon; Nadyne Girard; Jennifer S Haas; Bettina Habib; Usman Iqbal; Jack Li; Therese Sheppard
Journal:  J Am Geriatr Soc       Date:  2020-03-17       Impact factor: 5.562

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.